Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing KOMET-001 Phase 1b/2 study of Ziftomenib monotherapy in NPM1-mutant R/R AML presented at the ASCO Conference.

Ticker(s): KURA

Who's the expert?

Institution: Cancer Care Centers of South Texas

Hematologist/Oncologist at Cancer Care Centers of South Texas
Specializing in the management of all adult solid tumors, lymphomas and leukemias.

Interview Goal

This conversation will focus on the recent ASCO 2025 data on the KOMET-001 Phase 1b/2 study of Ziftomenib monotherapy in NPM1-mutant R/R AML; meaningful update for KURA & SNDX to better understand how the utilization of these two therapies will shake out in this population.ill discuss the data and the impact on the broader SERD landscape.

Do you want answers to these questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.